Transactions
18
Insider / Roivant Sciences Ltd.
Fitzgerald Meghan
Director at Roivant Sciences Ltd.
- Company
- Roivant Sciences Ltd.
- First filing on record
- March 30, 2026
- Latest trade on record
- September 16, 2026
- SEC filings
- EDGAR ↗
Fitzgerald Meghan, Director at Roivant Sciences Ltd., has disclosed 18 transactions in ROIV, THC since March 30, 2026: 0 purchases (0 open-market buys) and 7 sales, worth about $4.3M at the reported prices. The latest was filed September 18, 2026, 2 days after the trade.
Open-market buys
0
Sales
7
Avg. disclosure lag
2.7d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Fitzgerald Meghan made no purchases and 7 sales worth $3.4M, plus 11 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Fitzgerald Meghan has traded 2 stocks on record; the largest by dollars is ROIV.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 8 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 8 | 202,666 | $880K |
| S | Open-market sale | 5 | 105,112 | $3.3M |
| A | Grant or award | 3 | 16,773 | — |
| D | Sale back to the company | 1 | 493 | $86K |
| F | Shares withheld for tax | 1 | 1,743 | $71K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 18 | 0 | 7 · $3.4M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ROIV | Other A | September 16, 2026 | September 18, 2026 | 2d | 10,531 | — | — | derivative | Form 4 ↗ | |
| ROIV | Other A | September 16, 2026 | September 18, 2026 | 2d | 5,054 | — | — | Form 4 ↗ | ||
| ROIV | Sell S | September 15, 2026 | September 17, 2026 | 2d | 400 | $40 | $16K | 10b5-1 plan | Form 4 ↗ | |
| ROIV | Sell S | September 15, 2026 | September 17, 2026 | 2d | 4,712 | $40 | $187K | 10b5-1 plan | Form 4 ↗ | |
| ROIV | Sell F | September 10, 2026 | September 14, 2026 | 4d | 1,743 | $41 | $71K | Form 4 ↗ | ||
| ROIV | Option / conversion M | September 8, 2026 | September 10, 2026 | 2d | 20,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| ROIV | Sell S | September 8, 2026 | September 10, 2026 | 2d | 20,000 | $40 | $798K | 10b5-1 plan | Form 4 ↗ | |
| ROIV | Option / conversion M | September 8, 2026 | September 10, 2026 | 2d | 20,000 | $9 | $176K | 10b5-1 plan | Form 4 ↗ | |
| ROIV | Option / conversion M | June 30, 2026 | July 2, 2026 | 2d | 10,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| ROIV | Sell S | June 30, 2026 | July 2, 2026 | 2d | 10,000 | $35 | $349K | 10b5-1 plan | Form 4 ↗ | |
| ROIV | Option / conversion M | June 30, 2026 | July 2, 2026 | 2d | 10,000 | $9 | $88K | 10b5-1 plan | Form 4 ↗ | |
| THC | Other A | May 27, 2026 | May 28, 2026 | 1d | 1,188 | — | — | derivative | Form 4 ↗ | |
| THC | Option / conversion M | May 22, 2026 | May 26, 2026 | 4d | 1,333 | — | — | derivative | Form 4 ↗ | |
| THC | Sell D | May 22, 2026 | May 26, 2026 | 4d | 493 | $174 | $86K | Form 4 ↗ | ||
| THC | Option / conversion M | May 22, 2026 | May 26, 2026 | 4d | 1,333 | — | — | Form 4 ↗ | ||
| ROIV | Option / conversion M | March 26, 2026 | March 30, 2026 | 4d | 70,000 | — | — | derivative | Form 4 ↗ | |
| ROIV | Sell S | March 26, 2026 | March 30, 2026 | 4d | 70,000 | $27 | $1.9M | Form 4 ↗ | ||
| ROIV | Option / conversion M | March 26, 2026 | March 30, 2026 | 4d | 70,000 | $9 | $616K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 18, 2026 | Form 4 | 0001349297-26-000010 | 2 | published | EDGAR ↗ |
| September 17, 2026 | Form 4 | 0001349297-26-000008 | 2 | published | EDGAR ↗ |
| September 14, 2026 | Form 4 | 0001349297-26-000006 | 1 | published | EDGAR ↗ |
| September 10, 2026 | Form 4 | 0001140361-26-036246 | 3 | published | EDGAR ↗ |
| July 2, 2026 | Form 4 | 0001349297-26-000004 | 3 | published | EDGAR ↗ |
| May 28, 2026 | Form 4 | 0001193125-26-245804 | 1 | published | EDGAR ↗ |
| May 26, 2026 | Form 4 | 0001193125-26-239938 | 3 | published | EDGAR ↗ |
| March 30, 2026 | Form 4 | 0001140361-26-012063 | 3 | published | EDGAR ↗ |
Other insiders at Roivant Sciences Ltd.
- Venker Eric President & Immunovant CEO 94 rows
- Sukhatme Mayukh President & CIO 49 rows
- Gold Daniel Allen Director 22 rows
- MANCHESTER KEITH S Director 22 rows
- Gline Matthew CEO 20 rows
- Epperly Melissa B, Director 19 rows
- QVT Financial LP Insider 19 rows
- Sutaria Saumya CEO 19 rows
- Torti Frank President and Vant Chair 17 rows
- Arbour Paola M Director 16 rows
Everyone on file, with contracts and lobbying under the company's name: Roivant Sciences Ltd..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 8 | 18 | March 30, 2026 | September 18, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.